US-focused specialty pharma making complex generics, nasal-spray drug-devices and branded CNS drugs.
Price
Market Cap
Sector
Healthcare
Rank
| Line item | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 | FY26 |
|---|---|---|---|---|---|---|---|---|
| LiabilitiesEquity Capital | 5 | 5 | 5 | 5 | 15 | 15 | 15 | 17 |
| Reserves | 335 | 369 | 300 | 281 | 370 | 526 | 632 | 1.3k |
| Borrowings | 30 | 93 | 175 | 320 | 425 | 418 | 568 | 311 |
| Other Liabilities | 60 | 71 | 79 | 144 | 300 | 493 | 567 | 727 |
| Total Liabilities | 430 | 538 | 560 | 750 | 1.1k | 1.5k | 1.8k | 2.3k |
| AssetsFixed Assets | 157 | 188 | 193 | 199 | 307 | 327 | 501 | 532 |
| CWIP | 2 | 6 | 3 | 25 | 10 | 7 | 34 | 40 |
| Investments | 19 | 14 | 0 | 0 | 0 | 0 | 0 | 27 |
| Other Assets | 252 | 330 | 364 | 526 | 793 | 1.1k | 1.2k | 1.7k |
| Total Assets | 430 | 538 | 560 | 750 | 1.1k | 1.5k | 1.8k | 2.3k |
| Line item | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|---|
| ActivitiesCash from Operating | 5 | 62 | -63 | -75 | 21 | 159 | 205 |
| Cash from Investing | -84 | -46 | -46 | -32 | -68 | -65 | -410 |
| Cash from Financing | 80 | 52 | 63 | 123 | 44 | -40 | 283 |
| SummaryCapital Expenditure | — | — | — | — | — | — | — |
| Free Cash Flow | -54 | -10 | -117 | -119 | -35 | 91 | -24 |
| FCF Margin | — | — | — | — | — | — | — |
The Earnings Per Share over the last 12 months.
Your assumption of the company's expected yearly EPS growth (e.g., 6 for 6%).
Pre-filled with the lower of median (51.9×) and current (100.1×) PE — the conservative anchor.
The annualized return you aim to achieve. We solve for the price that delivers it, then compare to today's price.
At 10% growth and a 52× exit, ₹1520 only delivers your return if you pay ₹547. The price is currently baking in 32% growth.
EPS grows 10%/yr for 5 years, then fades to 6% over 2, exits at 52×.
| Year | Growth | EPS (₹) |
|---|---|---|
| FY27 | 10.0% | 16.71 |
| FY28 | 10.0% | 18.38 |
| FY29 | 10.0% | 20.22 |
| FY30 | 10.0% | 22.24 |
| FY31 | 10.0% | 24.46 |
| FY32 | 8.0% ·fade | 26.42 |
| FY33 | 6.0% ·fade | 28.01 |
Methodology: we discount normalized net profit as a proxy for owner earnings (an earnings-power approximation — not full free cash flow). Terminal growth is capped at 6% (≈ nominal GDP) regardless of the required return. This is an analytical tool, not investment advice.
Guides on how to read this kind of business and the numbers that matter.